RA Drug Available in New Autoinjector Device

Orencia is approved to treat moderately-to-severely active rheumatoid arthritis
Orencia is approved to treat moderately-to-severely active rheumatoid arthritis

Bristol-Myers Squibb announced the launch of Orencia (abatacept) ClickJect Autoinjector, a new autoinjector for adults with moderate to severe rheumatoid arthritis

The Orencia ClickJect automatically delivers a 125mg/mL dose subcutaneously with the push of a button and the user holding for 15 seconds. The step-by-step directions help patients with the injection process and its large viewing window with blue indicator help confirm the injection of a full dose. The lightweight device has a non-slip grip design for better control in patients with compromised dexterity. The ClickJect's transparent tip automatically locks and covers the needle post-injection. 

The usability and acceptability of the Orencia ClickJect was evaluated in a summative study (n=48) where patients rated comfort (P=0.0157), control (P=0.0002), ease of use (P=0.0210), and confidence of dose (P=0.896). Mean scores for the device ranged from 6.4–6.9 on a 7-point scale. 

Related Articles

Orencia, a selective costimulation modulator, is approved to reduce signs/symptoms, induce major clinical response, inhibit progression of structural damage, and improve physical function in patients with moderately-to-severely active rheumatoid arthritis and may be used alone or with DMARDS other than TNF antagonists. It is also indicated to reduce signs/symptoms of moderately-to-severely active polyarticular juvenile idiopathic arthritis in patients ≥6 years of age and may be used alone or with methotrexate.

Orencia is now available as a prefilled syringe, Autoinjector, and lyophilized powder for IV infusion. 

For more information call (800) ORENCIA or visit OrenciaHCP.com.

Loading links....